Sun Ya-Hui, Ma Yan, Chen Liang, Li Hai-Rong, Liang Xian-Wen, He Xiong-Hui, Zou Ke-Jian
Department of Gastrointestinal Surgery, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China.
Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China.
Front Immunol. 2025 Jul 18;16:1611281. doi: 10.3389/fimmu.2025.1611281. eCollection 2025.
Synchronous multiple gastric cancers (SMGC) represent a rare clinical entity with no established treatment guidelines. We report a 76-year-old female with two synchronous poorly differentiated adenocarcinomas (dMMR/MSI-H phenotype) in the gastric lesser curvature, clinically staged as cT4bN2M0. Following three cycles of neoadjuvant immunochemotherapy, the patient demonstrated remarkable tumor regression (RECIST 1.1 partial response) and subsequently underwent R0 distal gastrectomy. Histopathological examination confirmed a pathological complete response (ypT0N0, TRG 0).To our knowledge, this represents the first documented case of SMGC achieving pCR with neoadjuvant immunochemotherapy. Our findings suggest that PD-1 inhibition combined with chemotherapy may induce profound tumor regression in SMGC, even in cases with high tumor burden, potentially converting unresectable to resectable disease. This case provides compelling evidence for incorporating immunotherapy in SMGC management and warrants further investigation through clinical trials.
同步性多原发性胃癌(SMGC)是一种罕见的临床实体,目前尚无既定的治疗指南。我们报告了一名76岁女性,其胃小弯处有两个同步性低分化腺癌(错配修复缺陷/微卫星高度不稳定表型),临床分期为cT4bN2M0。经过三个周期的新辅助免疫化疗后,患者肿瘤显著消退(RECIST 1.1标准部分缓解),随后接受了R0远端胃切除术。组织病理学检查证实为病理完全缓解(ypT0N0,TRG 0)。据我们所知,这是首例记录在案的通过新辅助免疫化疗实现病理完全缓解的SMGC病例。我们的研究结果表明,PD-1抑制联合化疗可能会使SMGC肿瘤显著消退,即使是肿瘤负荷较高的病例,也有可能将不可切除的疾病转化为可切除的疾病。该病例为在SMGC治疗中纳入免疫治疗提供了有力证据,值得通过临床试验进一步研究。